This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
No
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Risk for travelers is very low. Transmitted by triatomine ("kissing") bugs in rural Latin America, especially in mud/thatch dwellings. Use bed nets, avoid sleeping in rural adobe structures. Screening after travel is recommended if you stayed in rustic accommodations in endemic areas.
Chronic parasitic disease caused by Trypanosoma cruzi, transmitted primarily by triatomine bugs ("kissing bugs"). Affects 6–7 million people worldwide. Can cause fatal cardiomyopathy and megaviscera decades after initial infection.
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Edema | 35% | Mild | Early |
| Skin ulcer | 30% | Mild | Early |
| Conjunctivitis | 20% | Mild | Early |
| Fever | 80% | Mild | Early |
| Hepatomegaly | 30% | Mild | Early |
| Malaise | 70% | Mild | Early |
| Swollen lymph nodes | 60% | Mild | Early |
| Abdominal pain | 25% | Mild | Early |
| Diarrhea | 20% | Mild | Early |
| Headache | 50% | Mild | Early |
| Irritability | 25% | Mild | Early |
| Loss of appetite | 50% | Mild | Early |
| Myalgia | 45% | Mild | Early |
| Nausea | 30% | Mild | Early |
| Rash | 15% | Mild | Early |
| Splenomegaly | 25% | Mild | Early |
| Tachycardia | 15% | Moderate | Early |
| Bradycardia | 25% | Moderate | Late |
| Constipation | 8% | Moderate | Late |
| Dysphagia | 10% | Moderate | Late |
| Bloating | 8% | Mild | Late |
| Chest tightness | 30% | Moderate | Late |
| Fatigue | 75% | Mild | Any phase |
| Shortness of breath | 12% | Moderate | Any phase |
Chagas disease (American trypanosomiasis) is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi. The disease is primarily transmitted to humans through the infected feces of triatomine bugs (subfamily Triatominae), commonly known as "kissing bugs" because they typically bite the face during sleep. Other transmission routes include oral transmission (contaminated food/juice), congenital (mother-to-child), blood transfusion, organ transplantation, and rare laboratory accidents.
Chagas disease affects an estimated 6–7 million people worldwide, predominantly in 21 Latin American countries where it is endemic. It causes approximately 10,000 deaths per year and is a major cause of cardiac morbidity in the Americas. Due to population migration, Chagas disease is now also found in non-endemic countries including the United States, Spain, Italy, France, Switzerland, Japan, and Australia, where it primarily affects Latin American immigrants.
The disease has two clinical phases: an acute phase (usually asymptomatic or mild) and a chronic phase that develops over decades. Approximately 20–30% of chronically infected individuals develop severe cardiac or gastrointestinal complications. Chagas disease is often called a "silent and silenced disease" because it progresses insidiously, predominantly affects impoverished rural populations, and has historically received insufficient attention and funding.
Chagas disease is a zoonotic parasitic disease with a complex life cycle involving triatomine insect vectors, mammalian reservoir hosts, and the protozoan Trypanosoma cruzi.
Key facts:
Causative agent: Trypanosoma cruzi, a flagellated kinetoplastid protozoan with multiple genetic lineages (TcI through TcVI) associated with different clinical outcomes
Vector: Over 130 triatomine species; Triatoma infestans, Rhodnius prolixus, and Triatoma dimidiata are the most important domestic vectors
Reservoir hosts: >100 mammalian species, including domestic dogs, cats, guinea pigs, opossums, armadillos, and rodents
Incubation period: 1–2 weeks after vector-borne infection; 20–40 days after transfusion-transmitted infection; congenital cases: transmission occurs in utero; serological diagnosis reliable at 8–10 months of age (after maternal antibody waning)
Global burden: 6–7 million infected; ~75 million at risk; ~10,000 deaths/year; ~8,000 newborns congenitally infected/year
Transmission routes (in order of importance):
Seek emergency medical care if any of the following occur, especially in individuals from or with travel to Latin America:
Acute Chagas disease emergencies:
Acute myocarditis — chest pain, palpitations, dyspnea, orthopnea, peripheral edema; can progress rapidly to cardiogenic shock, particularly in children
Meningoencephalitis — altered consciousness, seizures, focal neurological deficits; more common in immunocompromised patients and young children
High fever with periorbital edema (Romaña sign) — indicates active acute infection requiring immediate treatment
Chronic Chagas cardiac emergencies:
Syncope or near-syncope — may indicate high-grade AV block or ventricular tachycardia; sudden cardiac death is the leading cause of mortality in chronic Chagas
Severe palpitations or documented arrhythmias — sustained ventricular tachycardia is common and may be refractory
Signs of heart failure — progressive dyspnea, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, jugular venous distension
Stroke symptoms — sudden weakness, facial droop, speech difficulty, visual changes; thromboembolic events are frequent due to cardiac mural thrombi and apical aneurysms
Chronic Chagas gastrointestinal emergencies:
Sigmoid volvulus — severe abdominal distension, obstipation, and abdominal pain in patients with megacolon; requires urgent surgical intervention
Fecal impaction — massive fecaloma can cause bowel perforation and peritonitis
Severe dysphagia or aspiration — megaesophagus can lead to aspiration pneumonia
Immunocompromised reactivation: Patients with HIV/AIDS or post-transplant immunosuppression may experience fulminant reactivation with brain abscesses (chagasic meningoencephalitis) or severe myocarditis — this is a medical emergency with high mortality.
Most common signs and symptoms
Chagas disease presents in two distinct clinical phases, each with characteristic features.
Acute phase (first 4–8 weeks):
Asymptomatic in the majority (~70–80%) of vector-borne cases
When symptomatic: fever, malaise, headache, myalgia, and lymphadenopathy
Romaña sign — unilateral painless periorbital edema and conjunctivitis, occurring when T. cruzi enters through the conjunctiva; pathognomonic but seen in only ~5% of acute cases
Chagoma — localized indurated swelling at the site of parasite entry through the skin
Hepatosplenomegaly and generalized lymphadenopathy
Severe acute disease (rare, ~1–5%): acute myocarditis or meningoencephalitis, particularly in young children and immunocompromised patients; can be fatal
Oral transmission outbreaks tend to produce more severe acute illness with higher parasitemia
Chronic phase:
Indeterminate form (60–70%): Positive serology but no symptoms and no detectable organ damage on standard investigations; may persist lifelong
Cardiac form (20–30%): Develops over 10–30 years after initial infection
Digestive form (~10%): Progressive dilation of the esophagus (megaesophagus — dysphagia, regurgitation, aspiration) and/or colon (megacolon — chronic constipation, fecaloma, sigmoid volvulus)
Cardiodigestive form: Both cardiac and digestive involvement
Knowing the symptoms is the first step to a quick response.
Chagas disease follows a biphasic clinical course with an acute phase followed by a lifelong chronic phase if untreated.
Phase 1 — Acute infection (weeks 1–8):
Parasites enter through the bite wound, mucous membranes, or oral mucosa
Local multiplication at the entry site produces a chagoma or Romaña sign
Parasites disseminate hematogenously to tissues, particularly cardiac muscle, smooth muscle, and reticuloendothelial cells
High parasitemia detectable by microscopy
Immune response controls parasitemia within 4–8 weeks; symptoms resolve spontaneously in most cases
Without treatment, the infection is not cleared — parasites persist in tissue niches
Phase 2 — Chronic indeterminate phase (years to decades):
Begins after resolution of the acute phase
Positive serology with no symptoms and no detectable organ damage
Very low-grade parasitemia (detectable only by PCR or xenodiagnosis)
This phase may last the entire lifetime in 60–70% of infected individuals
The host-parasite equilibrium is maintained by a robust but insufficient immune response
Phase 3 — Chronic determinate disease (20–30% of patients, develops 10–30 years after infection):
Cardiac form: Progressive myocardial fibrosis and inflammation → conduction defects → arrhythmias → dilated cardiomyopathy → heart failure → death
Digestive form: Progressive neuronal destruction of the myenteric (Auerbach) plexus → megaesophagus and/or megacolon
Mixed cardiodigestive form: Both manifestations
Pathogenesis theories:
Parasite persistence: Ongoing low-grade infection drives chronic inflammation in target tissues
Autoimmunity: Molecular mimicry between T. cruzi antigens and host cardiac myosin may perpetuate tissue damage
Microvascular dysfunction: Ischemia from endothelial damage and microthrombosis contributes to fibrosis
Current evidence supports a combination of all three mechanisms
How this disease is identified
The diagnostic approach differs fundamentally between acute and chronic Chagas disease due to differences in parasitemia levels.
Acute phase diagnosis (high parasitemia):
Direct microscopy — fresh blood smear or buffy coat examination; sensitivity >80% in acute infection; trypomastigotes are visible as motile flagellated organisms
Microhematocrit concentration (Strout method) — concentrates parasites from blood; higher sensitivity than direct smear
PCR — highly sensitive; useful when parasitemia is low or for confirmation; also valuable for monitoring treatment response and detecting congenital infection in neonates
Thick blood smear with Giemsa staining — standard parasitological method
Chronic phase diagnosis (low/undetectable parasitemia):
Serology is the mainstay — WHO recommends two different serological tests using different antigen preparations for confirmation
ELISA — most widely used screening test; sensitivity >98%
Indirect fluorescent antibody (IFA) test — sensitivity >95%
Indirect hemagglutination (IHA) — simple, no specialized equipment needed
Rapid diagnostic tests (RDTs) — useful for screening in resource-limited settings; performance varies by brand
Discordant serology: When two tests disagree, a third test (often Western blot or radioimmunoprecipitation) is required for resolution — occurs in 2–5% of cases
Congenital Chagas disease:
Direct parasitological methods (microhematocrit) at birth — sensitivity 50–70%
If negative at birth, repeat serology at 8–10 months of age (after maternal antibodies wane)
PCR at birth has higher sensitivity (~90%) and is increasingly recommended
Organ assessment in chronic disease:
12-lead ECG — essential for all seropositive patients; RBBB + LAFB is the classic early finding
Echocardiography — evaluates ventricular function and regional wall motion abnormalities
Holter monitor — detects arrhythmias
Barium swallow and barium enema — assess megaesophagus and megacolon
Available treatment methods
Treatment of Chagas disease has two components: antiparasitic therapy to eliminate T. cruzi and management of organ-specific complications.
Antiparasitic treatment:
Benznidazole — first-line agent; adult dose: 5–7 mg/kg/day in 2 divided doses for 60 days. Cure rate >90% in acute infection and congenital cases; efficacy in chronic infection is debated but recommended for patients under 50 years, particularly those without advanced cardiomyopathy
Nifurtimox — alternative agent; adult dose: 8–10 mg/kg/day in 3 divided doses for 60–90 days. Similar efficacy to benznidazole but with a higher adverse event profile
Treatment indications:
Adverse effects (frequent, 30–40% of patients): Dermatitis (rash, photosensitivity), gastrointestinal symptoms (nausea, anorexia), peripheral neuropathy (benznidazole), and rarely bone marrow suppression
Management of chronic complications:
Chagas cardiomyopathy: Heart failure treated per standard guidelines (ACE inhibitors, beta-blockers, diuretics); amiodarone for ventricular arrhythmias; ICD implantation for secondary prevention of sudden death; anticoagulation for atrial fibrillation or apical aneurysm; cardiac transplantation for end-stage disease
Megaesophagus: Endoscopic balloon dilation for grade I–II; Heller cardiomyotomy for grade III; esophagectomy for grade IV
Megacolon: Dietary management and laxatives for mild cases; surgical resection (Duhamel or similar) for severe megacolon or complications
Most cases are effectively treated with early diagnosis.
How to protect yourself
There is no vaccine for Chagas disease. Prevention strategies target vector control, blood safety, and congenital screening.
Vector control (most effective intervention):
Indoor residual spraying (IRS) with pyrethroid insecticides (deltamethrin, lambda-cyhalothrin) — the cornerstone of Chagas control programs in the Southern Cone countries; highly effective against domestic triatomine populations
Housing improvement — replacing thatched roofs, adobe walls, and earthen floors with plastered walls, concrete, and metal roofing eliminates triatomine hiding places; cost-effective long-term solution
Insecticide-treated bed nets and curtains — supplementary measure
Regional initiatives (e.g., the Southern Cone Initiative since 1991) have interrupted vectorial transmission in Uruguay, Chile, Brazil, and parts of Argentina and Paraguay
Blood and organ safety:
Universal serological screening of blood donors for anti–T. cruzi antibodies — mandatory in all endemic countries and increasingly implemented in non-endemic countries with immigrant populations
Screening of organ donors from endemic areas
Congenital Chagas prevention:
Screening of pregnant women from endemic areas
Testing of neonates born to seropositive mothers
Early treatment of infected infants (cure rate >95% in the first year of life)
Oral transmission prevention:
Good hygiene in preparation of fruit juices, sugarcane juice, and açaí — pasteurization or heat treatment eliminates the parasite
Surveillance for contamination in food processing
Personal protective measures for travelers:
Sleep in well-constructed, sealed accommodations (not in traditional rural dwellings with thatched roofs)
Use bed nets if sleeping in endemic rural areas
Avoid fresh-squeezed juices from street vendors in outbreak-prone regions
Risk for short-term travelers is very low unless sleeping in rural adobe housing
Preparation is the best protection.
Risk assessment for travelers: The risk of Chagas disease for most travelers to Latin America is very low. Short-term tourists staying in standard hotels and urban accommodations face negligible risk of triatomine exposure. However, travelers engaging in specific activities may face elevated risk.
Higher-risk activities:
Sleeping in traditional rural housing (adobe, mud-brick, or palm-thatched dwellings) in endemic areas — this is the primary risk scenario for travelers
Eco-tourism or jungle lodges with rustic construction
Extended stays in rural endemic areas (volunteer work, research, missionary activities)
Consuming fresh-squeezed fruit juices from street vendors in areas with reported oral transmission outbreaks (especially açaí and sugarcane juice in the Amazon basin)
Endemic regions:
Highest risk: Bolivia (highest prevalence globally, ~6%), Argentina (Gran Chaco), Paraguay, rural Mexico, Central America, Colombia, Ecuador, Peru
Moderate risk: Brazil (northeast and Amazon), Venezuela
Imported disease hotspots: United States (~300,000 infected), Spain (~50,000–70,000), other European countries
Traveler precautions:
Sleep under bed nets in rural areas; ensure nets are tucked under the mattress
Inspect rural sleeping quarters for triatomines (1–3 cm, dark brown to black, usually hiding in wall cracks and under mattresses during the day)
Avoid sleeping in adobe or thatch-roofed dwellings
Avoid unprocessed fresh-squeezed juices from informal vendors in the Amazon basin
No prophylactic medication is available
Post-travel considerations:
Travelers who slept in rural endemic housing and develop fever, facial edema, or a skin nodule within 1–2 weeks should seek medical evaluation and mention Chagas disease risk
Long-term residents and immigrants from endemic areas should be screened serologically
Statistics and geographic data
Chagas disease is the most significant parasitic disease burden in the Americas and is increasingly recognized as a global health concern due to migration.
Global burden (WHO, 2024):
6–7 million people infected worldwide
75 million at risk of infection
~10,000 deaths per year (primarily from Chagas cardiomyopathy)
~8,000 congenital infections per year
~12,000 new vector-borne cases per year (declining due to vector control)
Economic burden estimated at $7.2 billion/year globally (including lost productivity)
Endemic countries (Latin America):
Bolivia — highest prevalence (~6.1% of population; >10% in some rural departments)
Argentina — ~1.5 million infected, predominantly in the Gran Chaco
Brazil — ~1–1.5 million infected; significant reduction through vector control
Mexico — ~1 million infected; multiple triatomine species
Colombia, Paraguay, Ecuador, Peru — hundreds of thousands infected in each
Central America — Guatemala, Honduras, and El Salvador have significant burdens
Non-endemic countries (imported Chagas):
United States — ~300,000 infected (Latin American immigrants); <30 cases of diagnosed chronic Chagas cardiomyopathy per year (massive underdiagnosis)
Spain — 50,000–70,000 infected (largest burden in Europe, primarily Bolivian immigrants)
Italy, France, Switzerland, UK, Japan, Australia — thousands of cases estimated in each
Trends and control achievements:
Vector-borne transmission interrupted in Uruguay (1997), Chile (1999), Brazil (2006), and parts of Argentina and Paraguay
Global incidence has declined by >70% since the 1990s due to vector control and blood screening
Major challenges remain: oral transmission outbreaks, congenital transmission (difficult to eliminate), climate change potentially expanding triatomine range, and massive underdiagnosis in non-endemic countries (estimated <1% diagnosed in the US and Europe)
Who is most at risk
Risk factors for Chagas disease encompass exposure to the vector, socioeconomic conditions, and host determinants of disease progression.
Risk factors for acquisition:
Residence in or travel to endemic areas — 21 countries in Latin America with active vectorial transmission
Poor-quality housing — adobe walls, palm-thatched roofs, earth floors, and wall cracks provide ideal triatomine habitats; the single strongest risk factor for vector-borne transmission
Rural residence in endemic areas, particularly the Gran Chaco region (Bolivia, Paraguay, Argentina)
Occupational exposure — agricultural workers in endemic areas
Blood transfusion from unscreened donors (mainly a historical risk; now rare in endemic countries)
Organ transplantation from infected donors
Maternal infection — 1–10% risk of congenital transmission per pregnancy
Oral exposure — consumption of food contaminated with triatomine feces (açaí, sugarcane juice, guava juice)
Risk factors for disease progression (indeterminate → determinate forms):
T. cruzi genetic lineage: TcII and TcV are more associated with cardiac disease; TcI with digestive forms in some regions
Parasite load during acute infection: Higher parasitemia is associated with worse long-term outcomes
Male sex: Men have a 1.5–2× higher risk of developing Chagas cardiomyopathy
Older age at infection: Later infection is associated with faster progression
Co-infections: HIV co-infection can cause severe reactivation; T. cruzi–HIV co-infection has 20–30% risk of CNS reactivation
Reinfection: Repeated exposure to T. cruzi in endemic areas may accelerate disease progression
Genetic factors: Polymorphisms in HLA, TNF-alpha, and CCR5 genes influence susceptibility to cardiomyopathy
Nutritional status: Malnutrition may impair immune control of parasite persistence
Potential complications
Chagas disease produces serious complications primarily through chronic cardiac and gastrointestinal involvement that develops over decades.
Cardiac complications (most important cause of morbidity and mortality):
Chronic Chagas cardiomyopathy (CCC): Develops in 20–30% of infected individuals; characterized by progressive myocardial fibrosis, inflammatory infiltration, and neuronal destruction leading to dilated cardiomyopathy
Conduction system disease: Right bundle branch block (RBBB) and left anterior fascicular block (LAFB) are the earliest and most characteristic ECG findings; may progress to complete heart block requiring pacemaker implantation
Ventricular arrhythmias: Sustained and non-sustained ventricular tachycardia occur in 20–50% of patients with CCC; the leading mechanism of sudden cardiac death
Sudden cardiac death: Accounts for 55–65% of all Chagas cardiac deaths; may be the first manifestation of previously undiagnosed chronic disease
Apical ventricular aneurysm: Nearly pathognomonic for CCC; identified in 30–50% of patients with advanced disease; serves as substrate for ventricular arrhythmias and thrombus formation
Thromboembolic events: Stroke (ischemic), pulmonary embolism, and peripheral embolism from mural thrombi in the left ventricle or apical aneurysm; stroke risk is 2–3× higher in Chagas cardiomyopathy than in other dilated cardiomyopathies
Heart failure: Progressive biventricular failure; worse prognosis than non-Chagas dilated cardiomyopathy (5-year survival ~20% in NYHA III–IV)
Gastrointestinal complications:
Megaesophagus: Progressive esophageal dilation due to destruction of myenteric plexus neurons; stages I–IV based on degree of dilation; complications include aspiration pneumonia, esophageal cancer (7× increased risk), and severe malnutrition
Megacolon: Dilation primarily of the sigmoid colon; complications include sigmoid volvulus (surgical emergency, 10–20% mortality), fecal impaction, bowel perforation, and peritonitis
Immunosuppression-related complications:
Reactivation in HIV/AIDS: CNS involvement (chagasic meningoencephalitis with ring-enhancing brain lesions mimicking toxoplasmosis) and acute myocarditis; mortality 80–100% if untreated
Post-transplant reactivation: Occurs in 20–40% of heart transplant recipients with Chagas; requires surveillance and preemptive treatment
Expected outcomes and recovery
The prognosis of Chagas disease is highly variable, ranging from lifelong asymptomatic infection to severe organ damage and premature death.
Acute phase:
Self-limited in the vast majority (~95–99%) of cases
Acute mortality is <5% in vector-borne transmission, primarily in children under 2 years from myocarditis or meningoencephalitis
Oral transmission outbreaks may have higher acute mortality (up to 8–10%) due to heavier parasite loads
With antiparasitic treatment in the acute phase, parasitological cure rates exceed 90%
Chronic indeterminate phase:
60–70% of infected individuals remain in this form indefinitely, with a normal lifespan and no clinical symptoms
Annual rate of progression to determinate forms (cardiac/digestive) is approximately 2–5%
Chronic Chagas cardiomyopathy:
The leading cause of Chagas-related mortality; responsible for most of the ~10,000 annual deaths
Rassi score stratifies prognosis: low-risk patients have ~10% 10-year mortality; high-risk patients have >80% 10-year mortality
Predictors of poor outcome: NYHA class III–IV, low ejection fraction (<40%), ventricular tachycardia, left ventricular aneurysm, QRS duration >120 ms
Sudden cardiac death accounts for 55–65% of Chagas cardiac deaths; sustained ventricular tachycardia and complete heart block are the usual mechanisms
Heart transplantation has better outcomes in Chagas patients compared to other causes of dilated cardiomyopathy (70–80% five-year survival)
Digestive forms:
Megaesophagus: progressive if untreated, but surgical interventions provide good long-term outcomes
Megacolon: main risk is sigmoid volvulus and bowel perforation, which carry significant mortality if not treated surgically
The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useKnow which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.